Skip to content
  • About Us
    • About Epigral
    • Our Core Ethos
    • Board of Directors
    • Our Journey
    • R&D
    • Corporate Brochure
  • Products
    • Chlor Alkali
    • Chloromethanes
    • Hydrogen Peroxide
    • Epichlorohydrin
    • CPVC
    • Chlorotoluenes Value Chain
    • Product Flow Chart
  • Sustainability
    • Certifications
    • Environment Health and Safety
    • Corporate Social Responsibility
    • Sustainability Reports
  • Investors
    • Results
    • Information on Shareholders
    • Financial Snapshot and Graphs
    • Shareholding Pattern
    • Rating Rationale
    • Governance, Policies & Compliances
    • Dividend
    • FAQs
    • Key Contacts
  • Media
    • Digital Domain
    • Print Chronicles
    • Television Broadcasts
  • Careers
  • Contact us
  • About Us
    • About Epigral
    • Our Core Ethos
    • Board of Directors
    • Our Journey
    • R&D
    • Corporate Brochure
  • Products
    • Chlor Alkali
    • Chloromethanes
    • Hydrogen Peroxide
    • Epichlorohydrin
    • CPVC
    • Chlorotoluenes Value Chain
    • Product Flow Chart
  • Sustainability
    • Certifications
    • Environment Health and Safety
    • Corporate Social Responsibility
    • Sustainability Reports
  • Investors
    • Results
    • Information on Shareholders
    • Financial Snapshot and Graphs
    • Shareholding Pattern
    • Rating Rationale
    • Governance, Policies & Compliances
    • Dividend
    • FAQs
    • Key Contacts
  • Media
    • Digital Domain
    • Print Chronicles
    • Television Broadcasts
  • Careers
  • Contact us
  • About Us
    • About Epigral
    • Our Core Ethos
    • Board of Directors
    • Our Journey
    • R&D
    • Corporate Brochure
  • Products
    • Chlor Alkali
    • Chloromethanes
    • Hydrogen Peroxide
    • Epichlorohydrin
    • CPVC
    • Chlorotoluenes Value Chain
    • Product Flow Chart
  • Sustainability
    • Certifications
    • Environment Health and Safety
    • Corporate Social Responsibility
    • Sustainability Reports
  • Investors
    • Results
    • Information on Shareholders
    • Financial Snapshot and Graphs
    • Shareholding Pattern
    • Rating Rationale
    • Governance, Policies & Compliances
    • Dividend
    • FAQs
    • Key Contacts
  • Media
    • Digital Domain
    • Print Chronicles
    • Television Broadcasts
  • Careers
  • Contact us
  • About Us
    • About Epigral
    • Our Core Ethos
    • Board of Directors
    • Our Journey
    • R&D
    • Corporate Brochure
  • Products
    • Chlor Alkali
    • Chloromethanes
    • Hydrogen Peroxide
    • Epichlorohydrin
    • CPVC
    • Chlorotoluenes Value Chain
    • Product Flow Chart
  • Sustainability
    • Certifications
    • Environment Health and Safety
    • Corporate Social Responsibility
    • Sustainability Reports
  • Investors
    • Results
    • Information on Shareholders
    • Financial Snapshot and Graphs
    • Shareholding Pattern
    • Rating Rationale
    • Governance, Policies & Compliances
    • Dividend
    • FAQs
    • Key Contacts
  • Media
    • Digital Domain
    • Print Chronicles
    • Television Broadcasts
  • Careers
  • Contact us

Digital Domain

Explore the digital sphere, where we connect and share our narratives, innovations and industry perspectives through online platforms.

Epigral soars after Q4 PAT jumps over two-fold to Rs 82 cr

  • 4 May 2026

Epigral posts record Q4 revenue as profit rebounds sharply

  • 4 May 2026

Epigral bags EcoVadis Silver medal

  • 4 February 2026

Epigral reports Q1 FY26 PAT stood at Rs.160 Cr

  • 3 August 2025

Mr. Maulik Patel discussing future plans of Epigral Limited

  • 24 July 2025

Epigral to expand wind-solar hybrid power plant to 38.14 MW

  • 7 June 2025

Epigral reports Q4 FY25 consolidated PAT at Rs. 86.89 Cr

  • 6 May 2025

Epigral Q4 results: Net profit rises 13% YoY to Rs 87 cr in March quarter

  • 5 May 2025

Epigral Q4 net profit rises 13% to Rs 87 Crore

  • 5 May 2025

Epigral’s CPCV resin and compound receives NSF certification

  • 17 April 2025

Epigral secures NSF certification for CPVC

  • 17 April 2025

Epigral targets 20% annual growth, expects to more than double revenue by FY28

  • 24 February 2025

Epigral Q3 result: PAT more than doubles to Rs 103.63 cr

  • 27 January 2025

Multibagger Stock: Epigral yields 120% return in a year, 430% in over 3 years

  • 18 November 2024

Epigral consolidated net profit rises 114.00% in the September 2024 quarter

  • 9 November 2024

Board of Epigral approves doubling of capacity at Dahej

  • 9 November 2024

Epigral Q2 FY25 PAT up 111% to Rs. 81 Cr

  • 9 November 2024

Eprigral raises Rs. 333 crore via QIP issue

  • 25 October 2024
Previous Page1 Page2 Page3 … Page7 Next

Explore our solutions – Connect with Epigral

Important Links

  • Chlor Alkali
  • Chloromethanes
  • Hydrogen Peroxide
  • Epichlorohydrin
  • Chlorotoluenes Value Chain
  • CPVC
  • About Us
  • Chlor Alkali
  • Chloromethanes
  • Hydrogen Peroxide
  • Epichlorohydrin
  • Chlorotoluenes Value Chain
  • CPVC
  • About Us

Quick Links

  • Results
  • Our Journey
  • Environment Health and Safety
  • Corporate Social Responsibility
  • Careers
  • Contact us
  • Results
  • Our Journey
  • Environment Health and Safety
  • Corporate Social Responsibility
  • Careers
  • Contact us

Contact

Monday-Saturday: 08am-9pm
+91 79 29709600

Want to email us instead?
in**@*****al.com

At Epigral, we are at the forefront of India’s chemical industry, bringing solutions by providing essential derivatives and specialty chemicals.

© 2026 Copyrights Epigral Limited. All Rights Reserved.